IVD news

Roche Ventana PD-L1 Assay Gets CE Mark as NSCLC CDx

October 5, 2022

In a landmark announcement, Roche has revealed that its Ventana PD-L1 (SP263) Assay has received CE IVD approval, setting a new standard in the personalized treatment of non-small cell lung cancer (NSCLC). This cutting-edge diagnostic test now stands as a beacon of hope for patients with locally advanced and metastatic NSCLC, identifying those who are eligible for treatment with the groundbreaking immunotherapy, Libtayo (cemiplimab).

Bridging the Gap in Lung Cancer Treatment

Lung cancer remains the most prevalent and lethal cancer worldwide, with NSCLC accounting for up to 85% of all cases. The challenge of treating this disease lies in its late diagnosis, often at a stage where traditional therapies have limited efficacy. However, the advent of immunotherapy has introduced a new horizon of treatment options, necessitating precise diagnostic tools to identify suitable candidates.

The Role of Ventana PD-L1 (SP263) Assay

The Ventana PD-L1 (SP263) Assay is at the forefront of this medical evolution, designed to detect the expression of the PD-L1 protein on tumor and immune cells. The expression level of PD-L1 has been closely linked to the efficacy of PD-1/PD-L1 immunotherapy drugs, making it a critical factor in tailoring treatment plans for individual patients. The assay’s approval is based on the results of the Phase III EMPOWER-Lung 1 study, which underscored the potential of Libtayo monotherapy in improving patient outcomes.

Expanding Treatment Options with “Roche PD-L1”

With this CE mark approval, the Ventana PD-L1 SP263 Assay (Roche PD-L1) is the only CE IVD product in the market with NSCLC indications for four different immunotherapy drugs, thereby broadening the spectrum of treatment options available to oncologists and their patients. This development is a testament to Roche’s commitment to advancing personalized medicine and improving access to life-saving treatments.

Jill German, Head of Pathology Lab at Roche Diagnostics, highlighted the significance of this breakthrough: “With our companion diagnostics, we can ensure each patient receives the most appropriate targeted treatment. This approval not only broadens the treatment landscape for advanced lung cancer patients but also marks a pivotal step in our journey towards personalizing healthcare.”

A Step Towards Personalized Healthcare

The CE mark for the Ventana PD-L1 (SP263) Assay represents more than just a regulatory milestone; it signifies a shift towards a future where cancer treatment is tailored to the individual, maximizing efficacy while minimizing unnecessary exposure to potentially ineffective therapies. As the global medical community continues to make strides in the fight against lung cancer, the role of precise, reliable diagnostics will only become more crucial.

In embracing these advancements, we inch closer to a world where lung cancer, once a formidable foe, becomes a manageable condition, with patients receiving treatments designed for their specific biological makeup. The journey towards personalized healthcare is long and fraught with challenges, but with innovations like the Ventana PD-L1 (SP263) Assay, the path becomes clearer, offering new hope to those battling lung cancer.

Fondo Social Europeo dentro de la Ayuda a la Recuperación para la Cohesión y los Territorios de Europa (REACT-UE)

MED IVD HEALTHTECH S.L ha sido beneficiaria de la subvención de contratos de trabajo de la Comunidad de Madrid, cofinanciado por el Fondo Social Europeo dentro de la Ayuda a la Recuperación para la Cohesión y los Territorios de Europa (REACT-UE), a través del Programa Operativo Regional FSE, en el marco del Programa Impulso a la Contratación Estable de Jóvenes para la Recuperación Económica, gestionado por la Dirección General del Servicio Público de empleo de la Consejería de Economía, hacienda y empleo de la Comunidad de Madrid.

© 2024 Copyright MDx | MedTech IVD CRO.

MDx | MedTech IVD CRO

Dark mode is activated. Turn off